Dr. William Williams reports

BRIACELL'S PIVOTAL PHASE 3 METASTATIC BREAST CANCER STUDY EXPANDS TO LEADING CANCER CENTER

The Memorial Sloan Kettering Cancer Center has joined Briacell Therapeutics Corp.'s continuing pivotal phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.

Briacell's phase 3 study has more than 80 active clinical sites across 15 states, including Penn Medicine's Abramson Cancer Center, Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, and University of Arizona.

"We are pleased to welcome MSK as a clinical site in Briacell's phase 3 study," stated Dr. William V. Williams, Briacell's president and chief executive officer. "MSK is one of the world's leading cancer centres, and its participation expands patient access to the Bria-IMT regimen as we continue advancing a potential new therapeutic approach for heavily pretreated patients."

"We are pleased that MSK is now enrolling patients in Briacell's pivotal phase 3 study evaluating Bria-IMT for advanced breast cancer in patients with limited therapeutic options. We look forward to collaborating with Briacell," commented Phaedon Zavras, MD, the MSK breast medical oncologist and assistant attending physician who is serving as principal investigator for the MSK study site.

Briacell's pivotal phase 3 clinical study is evaluating Briacell's lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor, compared with physician's choice of treatment in advanced metastatic breast cancer (the Bria-ABC study).

The study's primary end point is overall survival. An interim analysis is planned after 144 deaths have occurred, comparing OS in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice. Briacell recently received a positive recommendation from the independent Data Safety Monitoring Board to continue the phase 3 study in metastatic breast cancer. At ASCO 2026, Briacell also announced positive phase 2 survival data in a similar metastatic breast cancer patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received Food and Drug Administration fast-track designation.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.